Summit Therapeutics is classified as operating in the Medicinal & Botanical Manufacturing industry, NAICS Code 325411.
Summit Therapeutics is a publicly traded company on using the ticker symbol SMMT.
Detailed information on company financials and operating reports can be found here:
: SMMT
Summit Therapeutics Annual Revenue and Growth Rate
Note: Summit Therapeutics's revenues are gauged from an analysis of company filings.
Investor Activity
Summit Therapeutics has actively raised capital from investors. These investors may include private investors, venture capital firms, or other investment vehicles.
Date
Investors
Percent Raised
Target Size
June 18, 2024
2
100%
$200 MM
Complete list of funding rounds and total amounts in the Company Report
Trademark Applications
Trademark applications show the products and services that Summit Therapeutics is developing and marketing.
Summit Therapeutics doesn't have any recent trademark applications, indicating Summit Therapeutics is focusing on
its existing business rather than expanding into new products and markets.
Trademarks may include brand names, product names, logos and slogans.
Trademark
Date
SUMMIT THERAPEUTICS Pharmaceutical products for the treatment, prevention, prophylaxis, recurrence prevention and diagnosis of disease states and conditions caused or exacerbated by the administration of broad spectrum antibiotics; pharmaceutical products for the treatment, prevention, prophylaxis, recurrence prevention and diagnosis of inflammatory-related diseases, cancers, diseases of the respiratory system, diseases of the central nervous system, neurodegenerative diseases, infectious diseases, gut dysbiosis and microbiome related diseases and conditions; pharmaceutical products for the promotion, restoration, and maintenance of a healthy microbiome
02/25/2022
IMBYODIF Pharmaceutical preparations for treatment of Clostridioides difficile infection; Pharmaceutical compositions for the treatment of Clostridioides difficile infection; Pharmaceutical formulations for the treatment of Clostridioides difficile infection; Antibiotics
07/01/2021
COQUERDI Pharmaceutical preparations for treatment of Clostridioides difficile infection; Antibiotics; Pharmaceutical formulations for treatment of Clostridioides difficile infection
09/30/2020
See all trademarks and details in the Full Report.
Market Share of Summit Therapeutics's Largest Competitors
A competitive analysis shows these companies are in the same general field as Summit Therapeutics, even though they may not compete head-to-head.
These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines.
The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies.
Competitive advantage comes from offering better pricing or superior products/service.
These companies are similar in business line and location to Summit Therapeutics.
While some companies compete with neighboring businesses for customers, other companies may compete to attract skilled employees.
These companies are in the same general field as Summit Therapeutics and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.